Ponesimod-d4
Ponesimod-d4 (ACT-128800-d4) is the deuterium labeled Ponesimod. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[2][3][4].
Product Specifications
Product Name Alternative
ACT-128800-d4
UNSPSC
12352005
Target
Isotope-Labeled Compounds; LPL Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Others
Solubility
10 mM in DMSO
Smiles
O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2C)/C(S/C1=C\C3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC
Molecular Formula
C23H21D4ClN2O4S
Molecular Weight
465.00
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Leukocyte cell-derived chemotaxin-2 (LECT2)
Recombinant Human Leukocyte cell-derived chemotaxin-2 (LECT2)
Recombinant Human Leukocyte cell-derived chemotaxin-2 (LECT2)
Recombinant Human Leukocyte cell-derived chemotaxin-2 (LECT2)